Statera Biopharma (STAB) Competitors $0.0001 0.00 (0.00%) As of 05/18/2026 02:20 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock STAB vs. ARDS, TRVN, NAVB, GNCA, and PXMDShould you buy Statera Biopharma stock or one of its competitors? MarketBeat compares Statera Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Statera Biopharma include Aridis Pharmaceuticals (ARDS), Trevena (TRVN), Navidea Biopharmaceuticals (NAVB), Genocea Biosciences (GNCA), and PaxMedica (PXMD). These companies are all part of the "pharmaceutical products" industry. STAB vs. ARDSSTAB vs. TRVNSTAB vs. NAVBSTAB vs. GNCASTAB vs. PXMDHow does Statera Biopharma compare to Aridis Pharmaceuticals?Statera Biopharma (NASDAQ:STAB) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and profitability. Is STAB or ARDS more profitable? Company Net Margins Return on Equity Return on Assets Statera BiopharmaN/A N/A N/A Aridis Pharmaceuticals N/A N/A N/A Do institutionals & insiders hold more shares of STAB or ARDS? 9.6% of Aridis Pharmaceuticals shares are held by institutional investors. 5.5% of Statera Biopharma shares are held by company insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media favor STAB or ARDS? In the previous week, Statera Biopharma had 1 more articles in the media than Aridis Pharmaceuticals. MarketBeat recorded 1 mentions for Statera Biopharma and 0 mentions for Aridis Pharmaceuticals. Aridis Pharmaceuticals' average media sentiment score of 0.00 beat Statera Biopharma's score of -1.80 indicating that Aridis Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Statera Biopharma Very Negative Aridis Pharmaceuticals Neutral Which has more risk and volatility, STAB or ARDS? Statera Biopharma has a beta of -0.08, meaning that its share price is 108% less volatile than the broader market. Comparatively, Aridis Pharmaceuticals has a beta of 49.37, meaning that its share price is 4,837% more volatile than the broader market. Which has preferable earnings & valuation, STAB or ARDS? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStatera BiopharmaN/AN/AN/AN/AN/AAridis PharmaceuticalsN/AN/A-$30.37M$0.090.00 SummaryAridis Pharmaceuticals beats Statera Biopharma on 4 of the 5 factors compared between the two stocks.How does Statera Biopharma compare to Trevena?Statera Biopharma (NASDAQ:STAB) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, media sentiment, risk, dividends, earnings and institutional ownership. Do insiders & institutionals believe in STAB or TRVN? 13.6% of Trevena shares are owned by institutional investors. 5.5% of Statera Biopharma shares are owned by company insiders. Comparatively, 2.7% of Trevena shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more risk & volatility, STAB or TRVN? Statera Biopharma has a beta of -0.08, meaning that its share price is 108% less volatile than the broader market. Comparatively, Trevena has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market. Is STAB or TRVN more profitable? Company Net Margins Return on Equity Return on Assets Statera BiopharmaN/A N/A N/A Trevena N/A N/A -119.55% Which has higher valuation and earnings, STAB or TRVN? Statera Biopharma has higher earnings, but lower revenue than Trevena. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStatera BiopharmaN/AN/AN/AN/AN/ATrevena$443K0.02-$40.29M-$47.04N/A Does the media refer more to STAB or TRVN? In the previous week, Statera Biopharma had 1 more articles in the media than Trevena. MarketBeat recorded 1 mentions for Statera Biopharma and 0 mentions for Trevena. Trevena's average media sentiment score of 0.00 beat Statera Biopharma's score of -1.80 indicating that Trevena is being referred to more favorably in the news media. Company Overall Sentiment Statera Biopharma Very Negative Trevena Neutral SummaryTrevena beats Statera Biopharma on 5 of the 8 factors compared between the two stocks.How does Statera Biopharma compare to Navidea Biopharmaceuticals?Statera Biopharma (NASDAQ:STAB) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, media sentiment, dividends, profitability, valuation and risk. Which has more risk & volatility, STAB or NAVB? Statera Biopharma has a beta of -0.08, suggesting that its share price is 108% less volatile than the broader market. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, suggesting that its share price is 76% more volatile than the broader market. Do institutionals and insiders hold more shares of STAB or NAVB? 0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. 5.5% of Statera Biopharma shares are held by insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is STAB or NAVB more profitable? Company Net Margins Return on Equity Return on Assets Statera BiopharmaN/A N/A N/A Navidea Biopharmaceuticals N/A N/A N/A Which has preferable earnings & valuation, STAB or NAVB? Statera Biopharma has higher earnings, but lower revenue than Navidea Biopharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStatera BiopharmaN/AN/AN/AN/AN/ANavidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A Does the media favor STAB or NAVB? In the previous week, Statera Biopharma had 1 more articles in the media than Navidea Biopharmaceuticals. MarketBeat recorded 1 mentions for Statera Biopharma and 0 mentions for Navidea Biopharmaceuticals. Navidea Biopharmaceuticals' average media sentiment score of 0.00 beat Statera Biopharma's score of -1.80 indicating that Navidea Biopharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Statera Biopharma Very Negative Navidea Biopharmaceuticals Neutral SummaryNavidea Biopharmaceuticals beats Statera Biopharma on 6 of the 7 factors compared between the two stocks.How does Statera Biopharma compare to Genocea Biosciences?Statera Biopharma (NASDAQ:STAB) and Genocea Biosciences (NASDAQ:GNCA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk. Is STAB or GNCA more profitable? Statera Biopharma's return on equity of 0.00% beat Genocea Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Statera BiopharmaN/A N/A N/A Genocea Biosciences N/A -182.88%-62.76% Does the media refer more to STAB or GNCA? In the previous week, Statera Biopharma had 1 more articles in the media than Genocea Biosciences. MarketBeat recorded 1 mentions for Statera Biopharma and 0 mentions for Genocea Biosciences. Genocea Biosciences' average media sentiment score of 0.00 beat Statera Biopharma's score of -1.80 indicating that Genocea Biosciences is being referred to more favorably in the news media. Company Overall Sentiment Statera Biopharma Very Negative Genocea Biosciences Neutral Do insiders & institutionals have more ownership in STAB or GNCA? 0.6% of Genocea Biosciences shares are owned by institutional investors. 5.5% of Statera Biopharma shares are owned by company insiders. Comparatively, 1.6% of Genocea Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has higher earnings & valuation, STAB or GNCA? Statera Biopharma has higher earnings, but lower revenue than Genocea Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStatera BiopharmaN/AN/AN/AN/AN/AGenocea Biosciences$1.91M0.00-$33.20M-$0.61N/A Which has more volatility and risk, STAB or GNCA? Statera Biopharma has a beta of -0.08, indicating that its stock price is 108% less volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 1.61, indicating that its stock price is 61% more volatile than the broader market. SummaryGenocea Biosciences beats Statera Biopharma on 5 of the 9 factors compared between the two stocks.How does Statera Biopharma compare to PaxMedica?Statera Biopharma (NASDAQ:STAB) and PaxMedica (NASDAQ:PXMD) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk and profitability. Is STAB or PXMD more profitable? Statera Biopharma's return on equity of 0.00% beat PaxMedica's return on equity.Company Net Margins Return on Equity Return on Assets Statera BiopharmaN/A N/A N/A PaxMedica N/A -3,167.89%-560.35% Does the media favor STAB or PXMD? In the previous week, Statera Biopharma and Statera Biopharma both had 1 articles in the media. PaxMedica's average media sentiment score of 0.00 beat Statera Biopharma's score of -1.80 indicating that PaxMedica is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Statera Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Very Negative PaxMedica 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, STAB or PXMD? Statera Biopharma has a beta of -0.08, meaning that its share price is 108% less volatile than the broader market. Comparatively, PaxMedica has a beta of -0.99, meaning that its share price is 199% less volatile than the broader market. Which has stronger earnings & valuation, STAB or PXMD? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStatera BiopharmaN/AN/AN/AN/AN/APaxMedicaN/AN/A-$18.29M-$6.09N/A Do institutionals & insiders believe in STAB or PXMD? 4.9% of PaxMedica shares are held by institutional investors. 5.5% of Statera Biopharma shares are held by insiders. Comparatively, 1.0% of PaxMedica shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryStatera Biopharma beats PaxMedica on 4 of the 7 factors compared between the two stocks. Get Statera Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for STAB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding STAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip Chart STAB vs. The Competition ExportMetricStatera BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1K$756.00M$6.24B$12.23BDividend YieldN/A4.84%2.80%5.32%P/E Ratio0.001.4920.7925.05Price / SalesN/A115.23531.2172.68Price / CashN/A20.0743.0954.25Price / BookN/A7.939.816.83Net IncomeN/A-$3.49M$3.55B$335.69M7 Day PerformanceN/A-2.45%-2.11%-2.15%1 Month PerformanceN/A67.60%-4.14%-2.47%1 Year PerformanceN/A123.66%28.35%27.13% Statera Biopharma Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STABStatera BiopharmaN/A$0.00flatN/A+0.0%$1KN/AN/A20Negative NewsARDSAridis PharmaceuticalsN/A$0.00flatN/A+100.0%$11KN/A0.0030TRVNTrevenaN/A$0.01flatN/A-99.1%$11K$443KN/A40NAVBNavidea BiopharmaceuticalsN/AN/AN/AN/A$10K$8.13KN/A10GNCAGenocea BiosciencesN/AN/AN/AN/A$6K$1.91MN/A70 Related Companies and Tools Related Companies Aridis Pharmaceuticals Competitors Trevena Competitors Navidea Biopharmaceuticals Competitors Genocea Biosciences Competitors PaxMedica Competitors Genocea Biosciences Competitors Smart for Life Competitors Comera Life Sciences Competitors eFFECTOR Therapeutics Competitors Evelo Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:STAB) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredYour book attachedVeteran trader Bill Poulos is giving away his 'Simple Options Trading For Beginners' book - normally $29.97 - ...Profits Run | SponsoredThe one number Musk can't hide in the S-1When SpaceX files its S-1 in June, one number will stand out - power consumption. Running 1 million GPUs requi...Behind the Markets | SponsoredHe doesn't buy gold. He just profits from it.Former hedge fund manager Larry Benedict generated $274 million in profits - and Barron's ranked his fund in t...Brownstone Research | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Statera Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Statera Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
